Circulation Reports
Online ISSN : 2434-0790
Heart Failure
Urinary Isoxanthopterin in Heart Failure Patients
Masakazu HoriTeruhiko ImamuraNaoya KataokaMakiko NakamuraShuhei TanakaHiroshi OnodaRyuichi UshijimaMitsuo SobajimaNobuyuki FukudaHiroshi UenoShuji JohoKoichiro Kinugawa
著者情報
ジャーナル オープンアクセス HTML

2021 年 3 巻 11 号 p. 654-659

詳細
抄録

Background:The prognostic impact of urinary isoxanthopterin (U-IXP), a recently proposed marker of oxidative stress, in patients with heart failure remains unknown.

Methods and Results:Patients who were admitted to our institute for decompensated heart failure were prospectively included in the study; U-IXP was measured on admission. The association between the U-IXP concentration and a composite primary outcome that included cardiovascular death and heart failure readmissions following the index discharge was investigated. In all, 42 patients (median age 78 years [interquartile range {IQR} 69–85 years]; 25 males) were included in the study. The median U-IXP concentration on admission was 0.58 μmol/g creatinine (Cre; IQR 0.35–0.95 μmol/g Cre). A higher U-IXP concentration was an independent predictor of the primary outcome adjusted for clinical potential confounders and was associated with a significantly higher cumulative incidence of the primary outcome (71% vs. 16%, P=0.001) at a cut-off of 0.93 μmol/g Cre.

Conclusions:U-IXP on admission was associated with cardiovascular death or heart failure readmission following the index discharge in patients with decompensated heart failure. The clinical implication of aggressive interventions to normalize U-IXP and the detailed prognostic mechanism of U-IXP in heart failure patients remain the next concerns.

著者関連情報
© 2021, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
前の記事 次の記事
feedback
Top